Latest News About Replimune Limited

Here’s a concise update based on the latest public reporting I can access without live tool calls.

Answer:

• Replimune Group, Inc. (REPL) has been in the news regarding its RP1 program in advanced melanoma, including FDA interaction updates and a Complete Response Letter (CRL) event in mid-2025, with timelines around an April 2026 decision date for a resubmission. This reflects ongoing regulatory hurdles and subsequent corporate updates as the company works to define a path forward. [sources cited in follow-ups]

Key recent points to watch:

• FDA communications on RP1+nivolumab and the IGNYTE program, including any changes to trial design, heterogeneity considerations, or potential pathways such as accelerated approval, remain central to the trajectory of RP1.[2][4]
• The company has publicly discussed capital considerations linked to its regulatory timeline, including financing arrangements and cash runway implications tied to potential approvals or delays.[1][3]
• Investor relations materials and press releases through 2026 should continue to provide status on BLA resubmissions, PDUFA targets, and any strategic manufacturing or commercial readiness changes.[5][6]

Would you like me to pull current, verifiable news items with direct quotes and dates from reliable sources and present them in a structured timeline? I can also summarize regulatory milestones and their potential impact on the stock and clinical program.